Oncobesity News Posts

Despite soaring demand for GLP-1s, many eligible patients are unable to access these drugs for weight loss
In just a few short years, glucagon-like peptide-1 (GLP-1) receptor agonists have surged in popularity across the United States, transforming from specialized treatments for type 2 diabetes into revolutionary therapeutics for weight management, cardiovascular health and other emerging uses. But not all populations are benefiting from this expansion. As GLP-1 use has increased, disparities in access to these drugs have widened significantly, according to a new study led by researchers at Boston University School of Public Health (BUSPH).

Planning to Stop Taking a GLP-1? Here’s How to Maintain Weight Loss
Saturday, November 21 – Research shows that having an “exit strategy” after stopping at GLP-1 can help maintain your weight loss. coldsnowstorm · E+/Getty
A Cleveland Clinic study found that bariatric surgery and switching GLP-1 medications were associated with greater weight loss than discontinuing treatment entirely.
After two years, participants who underwent bariatric surgery lost an average of 28.2% of their body weight, compared with 16% among those who switched between semaglutide and tirzepatide and 4% among those who stopped GLP-1 treatment.

A doctor’s guide to surviving—and enjoying—holiday feasting while on GLP‑1 medication
Thanksgiving and the winter holidays bring celebration, connection and plenty of opportunities to come together with family and friends.

$1B-plus deal takes Innogen’s approved GLP-1 abroad
Innogen Pharmaceuticals has struck a potential $1 billion-plus licensing deal with Abu Dhabi’s Arcera Life Sciences. The deal will take its China-approved GLP-1 Diabegone (efsubaglutide alfa) to markets in four regions. It extends the globalization of China-originated metabolic drugs beyond the usual U.S. and European licensing route.

$3,900 GLP-1 Vacation; ‘Dr. Blanche’s Dispensary’ Scrutinized; Outbreak Hits Cruise
Saturday, November 21 – (MedPage Today) — Note that some links may require registration or subscription.
A woman opened up about her time at a week-long, $3,900 “GLP-1 Support Experience” hosted by an island resort. (Today)
The FDA announced the launch of a program…

Inside Look at Vacations Geared Toward People on GLP-1s
Friday, November 20 – Along with focusing on diet and exercise, health and wellness resorts across the country are now catering to the millions of people using GLP-1 weight loss drugs like Ozempic, Zepbound, Wegovy and Mounjaro. The programs include cooking lessons, guided strength-training sessions, and health counseling about those weight loss medicines. NBC’s Vicky Nguyen reports for TODAY.

I Paid $3,900 To Go on a ‘GLP-1 Vacation.’ Here’s What It Was Really Like
Friday, November 20 – Woman attends a GLP-1 vacation at a resort on Hilton Head Island, South Carolina. Hotels are offering experiences for guests taking the weight-loss drugs.

Why don’t weight-loss drugs like Ozempic and Wegovy work for everyone?
Friday, November 20 – Why do Ozempic and Wegovy produce dramatic weight loss for some people but disappointing results for others? Scientists are investigating whether the body’s hidden energy-saving response could help explain the difference and unlock more effective, personalized weight-loss treatments.

GLP-1 Reduced Binge Eating
Friday, November 20 – (MedPage Today) —
The FDA approved dexmedetomidine sublingual film (Igalmi) for at…

GLP-1 Eye Warning Leaves Patients, Doctors With a Difficult Choice
Friday, November 20 – (MedPage Today) — When someone loses vision in one eye while taking a GLP-1 drug, the first priority is an urgent eye examination. If the diagnosis is non-arteritic anterior ischemic optic neuropathy (NAION), the question that follows is: should…

1 in 10 U.S. adults reported GLP-1 medication use July to August 2025
Thursday, November 19 – From July to August 2025, about one in 10 U.S. adults reported taking a glucagon-like peptide-1 receptor agonist (GLP-1 RA) medication during the past year, according to research published in Morbidity and Mortality Weekly Report.

New guidance addresses GLP-1 medication use and eating disorders
Thursday, November 19 – GLP-1 medications are widely used to treat type 2 diabetes and help some people manage their weight. These medications can reduce appetite and help people feel full sooner. Early research also suggests they may help reduce binge-eating episodes for some people.

GLP-1s are being tied to unusual side effects — but are they to blame?
Thursday, November 19 – Reports of hair loss, nail detachment and vision problems highlight a persistent challenge for drug safety monitoring.

Semaglutide may improve eating disorder symptoms and body image in adults seeking obesity treatment
Thursday, November 19 – Adults receiving semaglutide for obesity treatment experienced greater improvements in several measures of disordered eating, eating disorder symptoms and body image concerns compared with participants receiving placebo, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania. The study was published in the International Journal of Eating Disorders.

GLP-1 weight-loss drugs linked to inadequate intake of key nutrients in some people
Thursday, November 19 – Drugs taken to suppress appetite, such as Wegovy and Mounjaro, are associated with inadequate intakes of key nutrients and energy in some people, finds a small exploratory study published in the journal BMJ Nutrition Prevention & Health.

Judge Recommends Novo Nordisk Get Win In GLP-1 TM Fight
Thursday, November 19 – A federal magistrate judge has recommended that a Florida-based digital health company be found liable for infringing Novo Nordisk’s trademark registrations on diabetes drug Ozempic and weight loss treatment Wegovy.

Why don’t GLP‑1 obesity drugs work for everyone?
Thursday, November 19 – Medications like Ozempic and Wegovy, which contain semaglutide—a GLP‑1 receptor agonist that helps regulate blood sugar, appetite and body weight—have become household names and important pillars in obesity management for the medical profession.

Serious Events Linked to GLP-1s; Implicit Bias Training in Medicine; Ebola in Kids
Wednesday, November 18 – (MedPage Today) — Note that some links may require registration or subscription.
Ischemic optic neuropathy, gastroparesis, thyroid C-cell tumors, gall stones, pancreatitis, and more — the Washington Post looks at some of the rare but serious…

Tirzepatide moves more than half of treated teens below obesity threshold, new clinical trial reports
Wednesday, November 18 – Tirzepatide (Zepbound) is a once-weekly injectable medication that hits two targets at once. This dual-action drug mimics the effects of two natural gut hormones in the body—glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Working together, these hormones keep blood sugar in check, slow the movement of food through the gut and signal the brain about fullness, which helps manage appetite and food intake.

Ozempic and Mounjaro may have a surprising effect on your brain
Wednesday, November 18 – Blockbuster weight loss drugs like Ozempic and Mounjaro may do more than help people shed pounds, with growing evidence suggesting they could also influence brain health. Although studies have linked GLP-1 medications to a lower risk of dementia, major trials found that semaglutide did not slow Alzheimer’s disease. Scientists suspect these drugs may be more effective at preserving memory and thinking abilities in people with obesity or diabetes, especially before cognitive problems appear.

Wegovy Reduces BMI in Kids With Obesity as Young as 6
Wednesday, November 18 – (MedPage Today) — NATIONAL HARBOR, Md. — Young children ages 6 to 11 years with obesity lost significant weight with the GLP-1 medication semaglutide (Wegovy), according to results from the phase III STEP Young trial.
At week 68, mean body…

STAT+: Newer GLP-1 drugs to combat obesity may be the next global battleground over access to medicines, expert warns
Wednesday, November 18 – How obesity medications may become the next big battleground over access to medicines in lower-income countries.

Ending Medicaid coverage for weight-loss drugs linked to sharp drop in GLP-1 use
Tuesday, November 17 – Medicaid prescriptions for weight loss–approved GLP-1 medications fell sharply after four states ended coverage of the drugs, according to a new study led by researchers at the University of Pittsburgh. The findings, published in JAMA, demonstrate how state coverage decisions can have an immediate and substantial effect on access to these medications.

GLP-1 Antagonist Shows Clinically Meaningful Results in Post-Bariatric Hypoglycemia
Tuesday, November 17 – (MedPage Today) — NATIONAL HARBOR, Md. — An investigational first-in-class GLP-1 receptor antagonist significantly reduced hypoglycemic events after bariatric surgery in the phase III LUCIDITY trial.
From a baseline mean of 2.39 events per…

Novo’s CagriSema drives more than 20% weight loss at lower doses
Tuesday, November 17 – As Novo awaits an FDA decision for its next-gen obesity asset, the company has presented more data at ObesityWeek that could help buoy sentiment on the amylin/GLP-1 combination that disappointed investors a couple of years ago.

STAT+: Pharmalittle: We’re reading about GLP-1 use, Covid-19 vaccine investment returns, and more
Tuesday, November 17 – Tuesday, November 17 – During July and August 2025, approximately 1 in 10 U.S. adults reported taking a GLP-1 medication during the previous year

Tirzepatide Cuts BMI in Adolescents With Obesity in Phase III Trial
Tuesday, November 17 – (MedPage Today) — NATIONAL HARBOR, Md. — Tirzepatide (Zepbound) yielded substantial reductions in BMI among adolescents with obesity or overweight with obesity-related complications, the phase III SURMOUNT-ADOLESCENTS trial showed.
At week…

What Was FDA’s GLP-1 Warning About?
Sunday, November 15 – (MedPage Today) — You passed medical training, now see if you can pass our weekly quiz

GLP-1s often contain untested additive combinations, study finds
Sunday, November 15 – Use of GLP-1 receptor agonist medications (GLP-1s) has skyrocketed in recent years, and many people are using “compounded” GLP-1 products: medicines that include GLP-1s as well as other active substances, some of which are not regulated by the FDA. A new study found that compounded GLP-1s now make up a large majority of weight-loss medicines, commonly containing vitamin B12 analogs that have not been tested for safety in combination with GLP-1s.

Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026
Saturday, November 14 – ObesityWeek 2026, which kicks off on Saturday, will spotlight presentations on the ascendant amylin pathway, as well as therapies looking to improve the quality of weight loss and patients’ persistence on treatment.

Study of 750,000 pregnancies reveals a surprising twist about Ozempic and Wegovy
Saturday, November 14 – A study of more than 750,000 pregnancies found that early exposure to Ozempic, Wegovy, and similar drugs was not linked to increased pregnancy complications when used for weight loss, but was associated with a higher risk of premature birth when prescribed for diabetes. The surprising difference suggests that diabetes itself may be driving the risk, although researchers caution that the drugs’ safety during pregnancy remains uncertain.

China approves first oral GLP-1 weight-loss pill
Saturday, November 14 – China has approved its first orally administered GLP-1 weight-loss drug, permitting Eli Lilly to sell its orforglipron pill in a market where 630 million adults could be overweight or obese by 2050.

Novel GLP-1 Cut Heavy Drinking Days in Alcohol Use Disorder
Saturday, November 14 – (MedPage Today) — The investigational glucagon/GLP-1 dual receptor agonist pemvidutide significantly reduced the number of heavy drinking days (HDDs) per week in patients with moderate-to-severe alcohol use disorder (AUD), the phase II RECLAIM…

Pfizer bero hero Blackstone funds GLP-1 run to $1.5B
Saturday, November 14 – Up to $1.5 billion from Blackstone Life Sciences for Pfizer Inc.’s push with GLP-1 prospect berobenatide (bero) will also help with the looming patent cliff, too, as the pharma giant faces loss of exclusivity for factor Xa inhibitor anticoagulant Eliquis (apixaban) in the spring of 2028.

Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns
Friday, November 13 – Thinking of quitting a GLP-1? A physician outlines six risks, from weight regain and muscle loss to worsening biomarkers and mental health consequences.

GLP-1 Drugs Linked to Improved Survival After Liver Transplant
Friday, November 13 – (MedPage Today) — Liver transplant patients who took a GLP-1 receptor agonist had a lower risk of death than those who weren’t on a GLP-1 drug, according to a retrospective three-center cohort study.
Among 2,402 patients, those on GLP-1 receptor…

Novel Glucagon/GLP-1 Agonist Meets Cardiovascular Safety Endpoint
Friday, November 13 – (MedPage Today) — Survodutide, an investigational glucagon receptor and GLP-1 receptor dual agonist, was safe for patients with obesity and either established cardiovascular disease (CVD), chronic kidney disease (CKD), or increased risk of CVD…

FDA Initiates Labeling Changes for GLP-1s Due to Rare But Serious Eye Disease Risk
Thursday, November 12 – A rare eye disease has been added to the growing list of side effects linked to GLP-1s, adding a second eye warning to several labels. Michael Siluk/UCG/Universal Images Group via Getty Images
The FDA is requiring new warnings on Ozempic, Wegovy, Mounjaro, Zepbound, and other GLP-1s about a potential increase in the risk of a rare eye condition that can cause sudden vision loss.
Regulators in the European Union, United Kingdom, and Australia have added similar warnings, mostly for semaglutide.

Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
Thursday, November 12 – Novartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about the risk of a rare eye condition that can lead to vision loss; and the agency is set to decide on no fewer than 11 therapies this month, including closely watched applications from Summit Therapeutics, Vertex and Capricor Therapeutics.

GLP-1 Pill Shows Benefit in Sleep Apnea
Thursday, November 12 – (MedPage Today) — The oral GLP-1 receptor agonist orforglipron (Foundayo) improved sleep-disordered breathing in patients with moderate-to-severe obstructive sleep apnea and overweight or obesity, two phase III trials showed.
For the treatment…